Twenty Years of Unrelated Donor Hematopoietic Cell Transplantation for Adult Recipients Facilitated by the National Marrow Donor Program

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 9 SUPPL., 2008, Pages 8-15

  Karanes, Chatchada ^a   Nelson, Gene O ^b   Chitphakdithai, Pintip ^b   Agura, Edward ^c   Ballen, Karen K ^d   Bolan, Charles D ^e   Porter, David L ^f   Uberti, Joseph P ^g   King, Roberta J ^b   Confer, Dennis L ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b NATIONAL MARROW DONOR PROGRAM   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^g KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Adult; Hematopoietic; National Marrow Donor Program; NMDP; Stem Cell; Transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE; HLA A ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DR ANTIGEN; MELPHALAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGE; AGED; APLASTIC ANEMIA; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE SEVERITY; DONOR SELECTION; EDITORIAL; ENGRAFTMENT; GRAFT REJECTION; GRAFT SURVIVAL; HEALTH PROGRAM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HODGKIN DISEASE; HUMAN; INTERNATIONAL COOPERATION; MAJOR CLINICAL STUDY; MORTALITY; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE CONDITIONING; PATIENT CARE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REDUCED INTENSITY CONDITIONING; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADULT; AGED; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; REGISTRIES; SURVIVAL RATE; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; UNITED STATES;

EID: 49449103753     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.06.006     Document Type: Editorial

References (16)

1. McCullough J., Perkins H.A., and Hansen J. The National Marrow Donor Program with emphasis on the early years. Transfusion 46 (2006) 1248-1255
2. Weisdorf D, Spellman S, Haagenson M, et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant. In press.
3. Flomenberg N., Baxter-Lowe L.A., Confer D., et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 104 (2004) 1923-1930
4. Kawase T., Morishima Y., Matsuo K., et al. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood 110 (2007) 2235-2241
5. Lee S.J., Klein J., Haagenson M., et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 110 (2007) 4576-4583
6. Morishima Y., Sasazuki T., Inoko H., et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 99 (2002) 4200-4206
7. Petersdorf E.W., Anasetti C., Martin P.J., et al. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood 104 (2004) 2976-2980
8. Petersdorf E.W., Hansen J.A., Martin P.J., et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 345 (2001) 1794-1800
9. Petersdorf E.W., Kollman C., Hurley C.K., et al. Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience. Blood 98 (2001) 2922-2929
10. Shaw B.E., Gooley T., Madrigal J.A., Malkki M., Marsh S.G.E., and Petersdorf E.W. Clinical importance of HLA-DPB1 in haematopoietic cell transplantation. Tissue Antigens 69 Suppl. 1 (2007) 36-41
11. Confer D.L., and Miller J.P. Optimal donor selection: beyond HLA. Biol Blood Marrow Transplant 13 (2007) 83-86
12. Hurley C.K., Wagner J.E., Setterholm M.I., and Confer D.L. Advances in HLA: practical implications for selecting adult donors and cord blood units. Biol Blood Marrow Transplant 12 (2006) 28-33
13. Kollman C., Howe C.W.S., Anasetti C., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 98 (2001) 2043-2051
14. Lee S.J., Kamani N., and Confer D.L. Principles and tools for selection of umbilical cord blood and unrelated adult donor grafts. Biol Blood Marrow Transplant 14 (2008) 112-119
15. Eapen M., Logan B.R., Confer D.L., et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant 13 (2007) 1461-1468
16. Bacigalupo A., Sormani M.P., Lamparelli T., et al. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation. Haematologica 89 (2004) 1238-1247